Kayne Anderson Rudnick Investment Management LLC Has $3.42 Million Position in Pfizer Inc. $PFE

Key Points

• Kayne Anderson Rudnick Investment Management LLC reduced its holdings in Pfizer Inc. by 33.0%, owning 134,919 shares valued at approximately $3.42 million as of the first quarter.
• Several institutional investors increased their positions in Pfizer, including Pacer Advisors Inc., which grew its stake by 856.8%, and Goldman Sachs Group Inc., which raised its stake by 51.9%.
• Pfizer recently announced a quarterly dividend of $0.43, reflecting an annualized payout of $1.72 and a yield of 6.8%.

Kayne Anderson Rudnick Investment Management LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 33.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 134,919 shares of the biopharmaceutical company's stock after selling 66,379 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC's holdings in Pfizer were worth $3,419,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Bessemer Group Inc. grew its position in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK grew its position in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp acquired a new stake in Pfizer during the first quarter worth approximately $8,283,000. Alta Advisers Ltd grew its position in Pfizer by 69.6% during the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after buying an additional 13,100 shares in the last quarter. Finally, WCM Investment Management LLC boosted its holdings in shares of Pfizer by 8.7% in the 1st quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after purchasing an additional 10,051 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Redburn Atlantic reduced their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. HSBC reduced their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Jefferies Financial Group raised their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Finally, The Goldman Sachs Group raised their target price on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Price Performance

Shares of PFE traded up $0.16 during trading hours on Wednesday, reaching $25.08. The stock had a trading volume of 31,814,192 shares, compared to its average volume of 44,824,848. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock has a market capitalization of $142.57 billion, a PE ratio of 13.34, a PEG ratio of 0.89 and a beta of 0.52. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company's 50-day moving average is $24.76 and its two-hundred day moving average is $24.40.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the prior year, the company earned $0.60 EPS. Pfizer's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.